This analysis identified a higher frequency of gene mutations in the high-risk group, notably involving pivotal genes such as KRAS, TP53, CDKN2A, SMAD4, and TTN, which are crucial drivers in the progression of PAAD [44,45,46]. This evidence concerns the gene CDKN2A and pancreatic adenocarcinoma.